PDUFA catalysts, FDA approvals, biotech pipeline analysis 📊 Newsletter: Every Mon (link below) 📄 Free FDA Catalyst Guide for subscribers
Los Angeles CA
Joined August 2023
- Tweets1.6K
- Following581
- Followers1.3K
- Likes837
$NVS’s Abogen deal puts a price on keeping its options open. The committed price is the upfront, not the headline total.
The Oct 2 agreement gives Novartis an exclusive worldwide license to ABO2203, an investigational mRNA-encoded CD19xCD3 T-cell engager aimed at autoimmune disease, plus exclusive options on other programs using Abogen’s RNA platform. The number of option programs and their targets were not disclosed.
Abogen receives $575M upfront. If every option is exercised and the agreed milestones are met, it is eligible for up to about $7.2B more, across development, regulatory, and commercial milestones, plus potential royalties. Closing still needs customary conditions, including regulatory clearances.
Novartis can expand its commitment as the platform develops, without choosing every program now. The next revealing decisions are which additional programs it licenses, and what evidence makes them worth funding.
abogenbio.com/news/company/n…)
For $ELVN, “superior” will come with a narrower question: superior to which drugs?
ENABLE-2, aligned with the FDA on Oct 6, randomizes about 450 previously treated CML patients 1:1 to relcobatinib 80 mg once daily or an investigator-selected second-generation TKI: dasatinib, nilotinib, or bosutinib. The primary endpoint is major molecular response at week 24. The key secondary is MMR at week 96.
The trial is powered so that a 10-point MMR improvement over that control arm is enough for statistical superiority. A win would be against the selected second-generation arm, not against each drug separately, and not against asciminib, imatinib, or ponatinib.
That limit matters for market share. Tolerability, durability, and physician placement still sit outside a single week-24 comparison. Enliven expects to start the trial before year-end. Results remain ahead.
[Trial design](ir.enliventherapeutics.com/n…)
$RNA’s agreed $50M raise includes about 6.3M new share equivalents. Counting only the common stock misses part of the dilution.
Atrium announced the private placement Oct 8. The agreement is dated Oct 7:
5,170,384 common shares at $7.93.
Pre-funded warrants for 1,134,930 shares, purchased at $7.929, with $0.001 left to exercise. They are immediately exercisable.
Gross proceeds are about $50M before fees. Management estimates net proceeds plus existing cash and investments fund operations through 2028. Closing is expected on or about Oct 9, subject to customary conditions.
Post-deal common shares outstanding are 22,276,027, and that count excludes the warrants. Exercise can be delayed by a 9.99% ownership cap. The economic dilution is still 6.3M shares.
The financing gives the heart-targeted RNA programs more time. Whether the evidence justifies the larger ownership base is the shareholder test.
[Company release](prnewswire.com/news-releases…)
$MRK’s subcutaneous Keytruda rollout now has a court order in eight European markets.
On Oct 7, $HALO said the Dutch patent court in The Hague found infringement of MDASE patent EP622 and ordered MSD BV to stop manufacturing and selling Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands. The order also bars facilitating affiliate infringement. IV Keytruda is outside it.
Germany was already under a preliminary injunction from December 2025. Merck disputes validity and infringement and is evaluating next steps. Keytruda SC uses Alteogen’s berahyaluronidase alfa. This is not a Halozyme license dispute.
The order puts friction on the new formulation. It does not remove the IV franchise. For Halozyme, the open question is whether the ruling produces a license, settlement, or other remedy. The announcement states no payment or royalty.
ir.halozyme.com/news/news-de…)
$TGTX’s Q2 2026 results show why a growing franchise can still produce lower earnings.
BRIUMVI U.S. net product revenue was $227.7M, up about 64% from $138.8M. Net income was $7.8M, down from $28.2M a year earlier.
The largest item inside R&D was $54.6M for subcutaneous manufacturing and secondary-manufacturer expenses. Total R&D was $95.3M vs $31.8M. SG&A rose to $82.1M from $55.6M on marketing, media, and personnel. Cost of revenue and interest also increased.
Commercialization is working. Expansion spending is absorbing part of the benefit. Those manufacturing charges are expensed as incurred, and 2026 guidance still includes about $100M for them. The next print can show whether that spend is rolling off. It cannot show subcutaneous conversion: Phase 3 data are guided for year-end 2026 or Q1 2027.
ir.tgtherapeutics.com/news-r…
$SMMT closed AstraZeneca’s $2B equity investment on Oct 5 and kept its existing development and commercial rights to ivonescimab.
The security is convertible preferred, about 108,955 shares at 1:1,000, implied $18.36. That is rights equivalent to about 12.0% of outstanding common, or about 10.6% fully diluted. Conversion still needs customary regulatory clearance.
On the Sone-Ve combination, each company supplies its own medicine and shares trial costs. AstraZeneca is intended to sponsor. No milestones, royalties, or profit share were disclosed. The same keep-your-own-drug structure applies to the separate Datroway collaboration. A broader ADC program is still an MOU.
The capital funds a larger ivonescimab program. Existing holders share the company with a new equity owner. The trade is whether the cash and combinations create more value per share than the stake sold at $18.36. Combination data matter more than the size of the cheque.
astrazeneca.com/media-centre…
What if the bigger obesity-drug opportunity is staying on treatment after the initial loss?
$VKTX initiated Part 2 of its VK2735 maintenance study on Oct 6. Design: 21 weeks of weekly injections, then daily or weekly oral tablets, or monthly or every-other-week injections, through Week 33. About 195 adults. Results guided for 2027.
Part 1 already tested less-frequent injections over the same 12-week window: up to 97% of Week-21 loss kept every other week, up to 90% monthly, versus 61% on placebo. Part 2 adds oral regimens. Weight change is exploratory; the stated objectives are safety, tolerability, and pharmacokinetics.
A tolerable maintenance option could extend time on therapy. Twelve weeks does not answer years of adherence or durable weight control.
Which would change your obesity-drug thesis more: greater initial weight loss, or an easier way to maintain it?
ir.vikingtherapeutics.com/20…
$PCVX’s commercial thesis needs more than counting 31 serotypes versus Capvaxive’s 21.
VAX-31 met all OPUS-1 primary endpoints. The co-primary allowed noninferiority against Prevnar 20 and/or Capvaxive: all 28 shared serotypes cleared LBCI >0.667 on that basis, and the three unique serotypes plus 20B met superiority.
The separate Capvaxive comparison is less clean. 17 of 19 shared serotypes met the >0.667 bar; serotypes 3 and 12F met only the historical >0.5 threshold. Versus Prevnar 20, 20 of 20 cleared >0.667.
These are OPA responses, not clinical protection. A model that displaces Capvaxive has to carry 3 and 12F. Broader serotype coverage is the stronger part of the package; disease-share figures are epidemiology, not trial outcomes.
BLA is planned for H1 2028, after OPUS-2/OPUS-3 (guided H1 2027) and manufacturing consistency. Vaxcyte, Oct 5.
globenewswire.com/de/news-re…
$ZYME funded part of the Theravance purchase by pledging the U.S. YUPELRI profit share, not the whole acquired cash stream.
Theravance was bought for $17 a share, about $929 million in cash. One piece is a $350 million non-dilutive, non-recourse note from OMERS Life Sciences, secured by the U.S. YUPELRI profit share. No shares were issued for that tranche. Zymeworks also put in about $217.5 million of its own cash after applying acquired Theravance cash. A contingent $100 million TRELEGY milestone, guided for the first quarter of 2027 if conditions are met, would offset part of that outlay.
Until the note is repaid, 75% of the YUPELRI profit-share cash flows go to principal and interest and Zymeworks retains 25%. After repayment, it retains 100% of those cash flows. The company has not guided repayment timing. Announcement materials cited an 8.25% coupon and 2036 maturity.
The denominator is the profit share, not sales. The acquired U.S. entitlement is 35% of YUPELRI net profits through Viatris. Ex-U.S. royalties are a separate entitlement and are not described as part of the 75% assignment. Non-recourse limits the lender to the YUPELRI collateral. It also means that stream’s first job is debt service.
The note avoids dilution and caps the lender’s claim. It does not make the acquired profit share free cash. Cash available for R&D is what remains after debt service. That financing choice belongs in the thesis.
zymeworks.gcs-web.com/news-r…
$IMNM paid BMS to retire the varegacestat and AL101 payment stack, not just to hand over a stake.
On October 2, Immunome entered Amendment No. 4 to the 2017 BMS license (Ayala origin, Immunome as assignee). It paid $20 million in cash and issued 4,425,487 new shares. After that consideration, it has no milestone, royalty, or other payment obligations to BMS under the license or the amendment. BMS assigned the related patents. On the 113.4 million shares outstanding at June 30, the issuance is about 3.9%.
The shares are a Section 4(a)(2) private placement. Immunome must use commercially reasonable efforts to file a resale registration by November 16, so the equity is a saleable claim, not a locked-up stake. BMS also keeps a perpetual, paid-up, non-exclusive license to those patents for molecules other than the licensed compounds and products.
If varegacestat or AL101 pays, Immunome keeps cash that would otherwise have gone to BMS. Existing holders own less of that residual. The filing does not disclose the milestone amounts or royalty rates retired, so the avoided stream is not a known number. Varegacestat’s desmoid NDA is already accepted, with a PDUFA date of April 28, 2027, which is the asset this price is mostly buying.
That is a capital-allocation trade: cash plus dilution against an undisclosed, contingent payment stack on an asset already in review. Better asset economics can create value. Value per share depends on the price paid.
sec.gov/Archives/edgar/data/…
$ALEC’s $100M Genentech upfront comes with a $15M payment to another licensor.
Alector’s Oct 5 filing shows the cash bridge: preliminary Sept 30 cash and investments of $138.7M become $223.7M after the initial Genentech and Spur payments. That’s an $85M increase.
Spur also gets a percentage in the teens of milestone and other non-royalty partnering income, plus a share of royalties Alector receives. Genentech’s additional $1.17B milestone ceiling is contingent, and those future receipts have obligations attached.
The deal strengthens Alector’s financing position; management projects runway into 2029. For shareholder value, the useful numbers are the cash retained and the development it can fund.
sec.gov/Archives/edgar/data/…
September’s FDA board is a good reminder that the date itself is not the product.
What mattered was identifying the specific regulatory question FDA actually had to answer.
-FAYUVI
Setup: prior CMC/facility CRL
Outcome: full approval
Read: manufacturing repair was the gating issue
-ATEBRIOZ
Setup: primary endpoint miss vs strong new-bone-volume signal
Outcome: approved
Read: FDA wrote the indication around reduction in new bone volume
-EMCITATE
Setup: serum-T3 endpoint passed; rescue + neurodevelopmental endpoints missed
Outcome: approved
Read: label narrowed to treatment of peripheral thyrotoxicosis in MCT8 deficiency
-CAMZYOS
Setup: positive randomized pediatric trial + existing monitoring framework
Outcome: approved
Read: final label uses a ≥30 kg pediatric boundary
-IFINATAMAB DERUXTECAN
Setup: strong single-arm response vs durability/ILD + accelerated-approval sufficiency
Outcome: BLA withdrawn
Read: the Phase 2 package did not clear the accelerated-approval bar
Five FDA setups.
Five different regulatory questions.
The calendar tells you when to look.
The failure mode tells you what to look for.
🤖 Made with AI
$INO / INO-3107 has an Oct. 30 FDA target for recurrent respiratory papillomatosis.
This one has an unusually important wrinkle:
INOVIO filed the BLA under accelerated approval.
FDA accepted the application, but assigned Standard Review, and its acceptance letter included a preliminary concern that the submission had not provided adequate information to justify accelerated-approval eligibility.
Since then, INOVIO says the late-cycle meeting and scheduled pre-license inspections have been completed.
So Oct. 30 contains two questions:
Does the evidence support INO-3107?
Does it support the accelerated-approval route INOVIO is asking FDA to use?
Genentech’s Oct. 9 FDA decision has two products in the filing:
• IV Tecentriq
• subcutaneous Tecentriq Hybreza
But clinically, it is one question.
ATOMIC tested Tecentriq + FOLFOX6 after surgery in stage III dMMR colon cancer.
At 36 months:
DFS: 86% vs 76%
Genentech reports a 50% reduction in the risk of recurrence or death versus chemotherapy alone.
So next week’s read is not “which formulation gets approved?”
It is whether FDA accepts the randomized ATOMIC evidence for adjuvant treatment of this biomarker-defined stage III population—and exactly how that population appears in the label.
One correction/refinement after reading the actual $BMY CAMZYOS approval:
The filing was discussed as an adolescent expansion for ages 12 to <18.
FDA’s approved U.S. indication is written differently.
CAMZYOS is now indicated for symptomatic oHCM in adults and pediatric patients weighing 30 kg or more.
SCOUT-HCM itself enrolled 44 patients ages 12 to <18, and the pediatric safety dataset described by BMS was in patients ≥35 kg.
Another reminder that the trial population, filing shorthand and final indication are related, but not necessarily identical.
The $WVE / WVE-006 setup is worth separating into two questions.
The proposed accelerated-approval case would rely on biomarkers:
• increasing healthy M-AAT
• reducing mutant Z-AAT
The full-approval case would come from completing the two-year registrational trial.
FDA agreeing that a biomarker can be used in a registrational strategy is not the same thing as FDA already concluding that the eventual biomarker result will support approval.
Wave still has to generate the data.
Next near-term read: the company says 600 mg monthly multidose data from RestorAATion-2 are due in Q4.
Regulatory pathway established.
Evidence still to come.
$WVE has an interesting FDA update this morning on WVE-006 in alpha-1 antitrypsin deficiency.
After meeting with FDA, Wave says it is planning one two-year registrational trial.
But that study potentially has two regulatory clocks:
Year 1: interim analysis that could support accelerated approval based on AATD biomarkers.
Year 2: completed trial intended to support full approval.
FDA also supports Wave’s current assay for measuring wild-type M-AAT and mutant Z-AAT protein.
The interesting part is the architecture: one trial potentially does the work of both an accelerated-approval filing and the evidence needed for full approval, rather than requiring a separate confirmatory study.
That can change the development timeline if the biomarkers and later clinical evidence behave as hoped.
September closes with another useful FDA distinction:
CAMZYOS did not need a new regulatory theory.
It had a positive randomized Phase 3 trial in adolescents, an established adult efficacy/safety framework and a defined pediatric population.
FDA approved the expansion today for symptomatic oHCM ages 12 to <18.
Contrast that with some of this month’s harder setups:
• Atebrioz — primary miss, narrower measurable-effect approval
• Emcitate — mixed evidence, specifically framed indication
• Ifinatamab deruxtecan — BLA withdrawn before the PDUFA date
• CAMZYOS — positive randomized pediatric expansion
Same FDA calendar.
Completely different evidentiary problems.
That is why the setup class matters more than the date.
$BMY / CAMZYOS — APPROVED
FDA has expanded Camzyos to adolescents ages 12 to <18 with symptomatic obstructive HCM.
That makes mavacamten the first cardiac myosin inhibitor approved for adolescent oHCM.
SCOUT-HCM randomized 44 patients. At Week 28:
• Valsalva LVOT gradient: −48.5 mmHg with Camzyos
• Placebo: −0.5 mmHg
• Between-group difference: −48.0 mmHg
• P<0.001
No patient experienced LVEF below 50%.
The efficacy question resolved cleanly. The next read is the pediatric label itself: dosing, monitoring and how adolescents enter the existing Camzyos safety framework.